INNOCARE PHARMA LIMITED — Investor Relations & Filings
About INNOCARE PHARMA LIMITED
InnoCare Pharma Limited is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of molecularly targeted therapies for cancer and autoimmune diseases. The company prioritizes the creation of first-in-class and best-in-class drugs to address significant unmet medical needs. Its flagship product, orelabrutinib, is a highly selective Bruton's tyrosine kinase (BTK) inhibitor utilized in the treatment of B-cell malignancies and investigated for autoimmune indications. InnoCare's pipeline includes a diverse range of candidates targeting solid tumors and hematological conditions, leveraging expertise in structural biology and precision medicine. The organization maintains integrated capabilities across research, clinical development, and manufacturing to support its global therapeutic programs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 诺诚健华医药有限公司2025年度审计报告 | 2026-03-25 | Chinese | |
| 诺诚健华医药有限公司关于修订《公司章程》的公告 | 2026-03-25 | Chinese | |
| InnoCarePharmaLimited（诺诚健华医药有限公司）提名委员会职权范围 | 2026-03-25 | Chinese | |
| InnoCarePharmaLimited（诺诚健华医药有限公司）股东大会议事规则 | 2026-03-25 | Chinese | |
| 诺诚健华医药有限公司关于调整募投项目内部投资结构的公告 | 2026-03-25 | Chinese | |
| 中国国际金融股份有限公司关于诺诚健华医药有限公司2025年度募集资金存放、管理与使用情况的核查意见 | 2026-03-25 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39364440 | 诺诚健华医药有限公司2025年度审计报告 | 2026-03-25 | Chinese | ||
| 39364359 | 诺诚健华医药有限公司关于修订《公司章程》的公告 | 2026-03-25 | Chinese | ||
| 39364351 | InnoCarePharmaLimited（诺诚健华医药有限公司）提名委员会职权范围 | 2026-03-25 | Chinese | ||
| 39364343 | InnoCarePharmaLimited（诺诚健华医药有限公司）股东大会议事规则 | 2026-03-25 | Chinese | ||
| 39364331 | 诺诚健华医药有限公司关于调整募投项目内部投资结构的公告 | 2026-03-25 | Chinese | ||
| 39364329 | 中国国际金融股份有限公司关于诺诚健华医药有限公司2025年度募集资金存放、管理与使用情况的核查意见 | 2026-03-25 | Chinese | ||
| 39364318 | 诺诚健华医药有限公司关于首次实现盈利暨取消股票简称标识U的公告 | 2026-03-25 | Chinese | ||
| 39364312 | 诺诚健华医药有限公司2025年年度报告摘要 | 2026-03-25 | Chinese | ||
| 39364306 | InnoCarePharmaLimited（诺诚健华医药有限公司）董事会议事规则 | 2026-03-25 | Chinese | ||
| 39364296 | 诺诚健华医药有限公司2025年年度报告 | 2026-03-25 | Chinese | ||
| 39364293 | 诺诚健华医药有限公司2025年度“提质增效重回报”行动方案的年度评估报告及2026年度“提质增效重回报”行动方案 | 2026-03-25 | Chinese | ||
| 39364288 | InnoCarePharmaLimited（诺诚健华医药有限公司）薪酬委员会职权范围 | 2026-03-25 | Chinese | ||
| 39364280 | 中国国际金融股份有限公司关于诺诚健华医药有限公司2025年度持续督导现场检查报告 | 2026-03-25 | Chinese | ||
| 39364275 | 中国国际金融股份有限公司关于诺诚健华医药有限公司调整募投项目内部投资结构的核查意见 | 2026-03-25 | Chinese | ||
| 39364265 | 港股公告:公司秘书、授权代表及法律程序代理人变更 | 2026-03-25 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
INNOCARE PHARMA LIMITED via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58414/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58414 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58414 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58414 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58414}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for INNOCARE PHARMA LIMITED (id: 58414)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.